Hydroxy, Bonded Directly To Carbon, Attached Directly Or Indirectly To The Acyclic Carbon Or Chain By Acyclic Nonionic Bonding (e.g., Beta Hydroxy Phenethylamines, Etc.) Patents (Class 514/653)
-
Patent number: 8987262Abstract: The present technology relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present technology provides an alternative to the known compounds, e.g. corticosteroïds, interferon or vincristine, generally used for the treatment of hemangiomas.Type: GrantFiled: November 16, 2012Date of Patent: March 24, 2015Assignees: Universite de Bordeaux, Centre Hospitalier Universitaire de BordeauxInventors: Christine Leaute-Labreze, Eric Dumas De La Roque, Alain Taieb, Jean-Benoit Thambo
-
Publication number: 20150079185Abstract: The invention relates to a method for making composite active particles for use in a pharmaceutical composition for pulmonary administration, the method comprising a milling step in which particles of active material are milled in the presence of particles of an additive material which is suitable for the promotion of the dispersal of the composite active particles upon actuation of an inhaler. The invention also relates to compositions for inhalation prepared by the method.Type: ApplicationFiled: November 25, 2014Publication date: March 19, 2015Inventors: JOHN NICHOLAS STANIFORTH, MATTHEW MICHAEL GREEN, DAVID ALEXANDER VODDEN MORTON
-
Publication number: 20150080384Abstract: Effective methods and compositions to deter abuse of pharmaceutical products (e.g., orally administered pharmaceutical products) including but not limited to immediate release, sustained or extended release and delayed release formulations for drugs subject to abuse comprising at least 10% by weight hydroxypropylcellulose; polyethylene oxide; and a disintegrant selected from the group consisting of crospovidone, sodium starch glycolate and croscarmellose sodium; wherein the ratio of hydroxypropylcellulose to polyethylene oxide on a weight basis is between about 10:1 and 1:10.Type: ApplicationFiled: November 24, 2014Publication date: March 19, 2015Applicant: ACURA PHARMACEUTICALS, INC.Inventors: Ronald L. LEECH, Rachelle L. HALL YUNG, Albert W. BRZECZKO
-
Publication number: 20150071969Abstract: Levalbuterol L-tartrate affords crystals possessing properties desirable for use in a metered dose inhaler.Type: ApplicationFiled: May 21, 2014Publication date: March 12, 2015Applicant: SUNOVION PHARMACEUTICALS INC.Inventors: Paul MCGLYNN, Roger Bakale, Craig Sturge
-
Publication number: 20150050337Abstract: Provided are controlled release pharmaceutical compositions comprising desvenlafaxine oxalate, one or more release rate controlling polymers, and pharmaceutically acceptable excipients.Type: ApplicationFiled: August 13, 2013Publication date: February 19, 2015Applicant: GENERIC PARTNERS PTY. LTDInventors: Subrata Kundu, Atul Patil, Nitin Borkar
-
Patent number: 8956662Abstract: The invention discloses a pharmaceutical composition comprising phenylephrine or a pharmaceutically acceptable salt thereof and an erodible layer which is for oral administration wherein the composition delivers phenylephrine or a pharmaceutically acceptable salt thereof via absorption in the colon. The pharmaceutical composition comprises a core comprising phenylephrine or a pharmaceutically acceptable salt thereof and an erodible layer which is in a time-dependent, pH-dependent, or colon-specific enzyme-dependent erodible layer that degrades to expose the core to release phenylephrine in the colon. In one preferred embodiment, the erodible layer encases the core. The composition optionally further comprises phenylephrine in the erodible layer or other additional layer(s).Type: GrantFiled: June 1, 2007Date of Patent: February 17, 2015Assignee: MSD Consumer Care, Inc.Inventors: David Monteith, John O'Mullane, Joseph P. Reo, Robert T. Nowak, Jiansheng Wan, Mohammed A. Kabir, Malaz A. Abutarif, Glenn E. Fritz
-
Patent number: 8946301Abstract: Methods and therapeutic compositions are disclosed for treating neurodegenerative disorders and, in particular Amyotrophic Lateral Sclerosis, using sphingosine1-phosphate receptor modulators, such as fingolimod or a pharmaceutically acceptable salt, hydrate, or solvate thereof.Type: GrantFiled: November 29, 2012Date of Patent: February 3, 2015Assignee: ALS Therapy Development InstituteInventors: Steven Perrin, John Lincecum, Alan Gill, Fernando Vieira
-
Patent number: 8946290Abstract: Active compound combinations of compounds of group A, particularly opioids such as (+)-(2R,3R)-1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol or a salt thereof with a physiologically tolerated acid, and compounds of group B, particularly anti-muscarine agents such as oxybutynin or a salt thereof with a physiologically tolerated acid suitable for treatment of an increased urge to urinate or urinary incontinence. Related pharmaceutical formulations and methods of treatment of an increased urge to urinate or urinary incontinence are also provided.Type: GrantFiled: September 23, 2011Date of Patent: February 3, 2015Assignee: Gruenenthal GmbHInventor: Thomas Christoph
-
Patent number: 8940796Abstract: An oral, aqueous-based, liquid pharmaceutical composition is provided. The composition comprises up to about 45% w/v glycerin and up to about 10% w/v sorbitol wherein the glycerin to sorbitol ratio is about 2:1 to 10:1.Type: GrantFiled: February 9, 2007Date of Patent: January 27, 2015Assignee: Wyeth LLCInventors: William Bubnis, Stephanie Shield, Amanda Alley
-
Publication number: 20150024046Abstract: The present invention relates to an abuse-proofed oral dosage form with controlled release of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol for once daily administration, which comprises the active ingredient and/or one or more of the pharmaceutically acceptable salts thereof (A), at least one synthetic or natural polymer (C), delayed-release auxiliary substances, optionally physiologically acceptable auxiliary substances (B) and optionally a wax (D), component (C) or (D) in each case exhibiting a breaking strength of at least 500 N, preferably of at least 1000 N.Type: ApplicationFiled: October 7, 2014Publication date: January 22, 2015Inventors: Johannes BARTHOLOMÄUS, Heinrich KUGELMANN, Elisabeth ARKENAU-MARIC
-
Patent number: 8937085Abstract: The present invention relates to a pharmaceutical carrier composition and a pharmaceutical composition comprising said pharmaceutical carrier composition. The pharmaceutical composition comprises: (a) at least 20% (w/w) of the composition of a sugar or a sugar alcohol; (b) one or more pharmaceutically acceptable excipients; (c) one or more pharmaceutically active ingredients in their base form; and (d) water up to 100% (w/w). The present pharmaceutical composition is especially resistant against flocculation, clumping and/or precipitation at room temperature during prolonged time-periods such as one or more years.Type: GrantFiled: February 13, 2008Date of Patent: January 20, 2015Assignee: Dafra Pharma N.V.Inventor: Frans Herwig Jansen
-
Publication number: 20150018358Abstract: Embodiments of the present invention are directed to compositions and methods for the treatment of purpura. Preferred compositions comprise an ? adrenergic receptor agonist selected from selective ?1 adrenergic receptor agonist, selective ?2 adrenergic receptor agonist, non-selective ?1/?2 adrenergic receptor agonist, agents with ?2 adrenergic receptor agonist activity and combinations thereof, in a pharmaceutically acceptable carrier in order to treat and improve the cosmetic appearance of hemorrhagic (purpuric) lesions in the skin.Type: ApplicationFiled: October 2, 2014Publication date: January 15, 2015Inventors: Stuart D. SHANLER, Andrew ONDO
-
Publication number: 20150018293Abstract: Compositions and methods for the treatment and control of various conditions in an animal which comprises administering to said animal an effective amount of a immediate release composition of about 0.5% to 50% wt/wt of active ingredient together with excipients to a total of about 100%, wherein said composition dissolves in a relatively short period of time, e.g., 75 seconds or less, 5 seconds or less, or 3 seconds or less, upon administration to said animal.Type: ApplicationFiled: May 12, 2014Publication date: January 15, 2015Applicant: NEWMARKET PHARMACEUTICALS LLCInventors: David ROCK, Mark RIDALL
-
Publication number: 20150011644Abstract: A therapeutic composition comprising: a methamphetamine precursor; a gel-forming polymer; an emulsifier with a lipid backbone; a disintegrant; and a surfactant; wherein the ratio of emulsifier to gel-forming polymer on a weight basis is between about 10:1 and 1:10.Type: ApplicationFiled: July 2, 2014Publication date: January 8, 2015Inventor: Ronald Leech
-
Patent number: 8920837Abstract: The novel sustained release dosage form comprising an active agent and a combination of a non-swelling pH dependent release retardant and a non swelling pH independent release retardant polymer which provides pH-independent drug release for a considerable period of time after administration.Type: GrantFiled: July 3, 2006Date of Patent: December 30, 2014Assignee: Rubicon Research Private LimitedInventors: Pratibha S. Pilgaonkar, Maharukh T. Rustomjee, Anilkumar S. Gandhi, Paras R. Jain, Atul A. Kelkar
-
Patent number: 8921386Abstract: A drug substance with a pharmaceutically acceptable organic acid addition salt of an opioid wherein said organic acid is selected from Structure A: wherein R1-R4 are independently selected from H, alkyl or substituted alkyl of 1-6 carbons, adjacent groups may be taken together to form a cyclic alkyl, cyclic alkyl-aryl, or cyclic aryl moiety; R5 is selected from H, or an alkali earth cation; R6 and R7 are independently selected from H, alkyl of 1-6 carbons, an alkali earth cation, and aryl of 6 to 12 carbons, in a number sufficient to complete the valence bonding of X, and wherein X is selected from nitrogen, oxygen or sulfur; and wherein the drug substance has a morphology selected from amorphous and crystalline.Type: GrantFiled: May 31, 2012Date of Patent: December 30, 2014Assignee: Pisgah Laboratories, Inc.Inventors: Clifford Riley King, Stephen G. D'Ambrosio, David W. Bristol, Michael L. English
-
Publication number: 20140378401Abstract: The ophthalmic drug delivery vehicles provide comfort and compliance; drug solubility, residence time and permeability; and reduce side effects. In addition, the delivery vehicle can be slightly modified to provide an artificial tear formulation.Type: ApplicationFiled: December 18, 2013Publication date: December 25, 2014Applicant: GNT, LLCInventor: Gerald Horn
-
Publication number: 20140371323Abstract: A solid pharmaceutical composition suitable for oral administration, comprising: (a) a S1P receptor modulator; (b) a filler, and (c) a cyclodextrin.Type: ApplicationFiled: March 30, 2012Publication date: December 18, 2014Applicant: Novartis AGInventor: Supriya Rane
-
Publication number: 20140363516Abstract: The present invention relates to a sustained-release pharmaceutical formulation, in particular a multiple unit pellet tablet (MUT) formulation for oral administration comprising a plurality of sustained-release pellets. The invention further relates to sustained-release pellets wherein the active agent is an opioid. The sustained-release pellets are suitable for the preparation of a multiple unit pellet tablet formulation.Type: ApplicationFiled: December 18, 2012Publication date: December 11, 2014Applicant: Hexal AktiengesellschaftInventors: Patrick Rother, Andreas Krekeler, Theresa Taeubrich, Christian Wawra, Ingeborg Mohry
-
Patent number: 8906392Abstract: Compositions, methods of making, and methods of using nanoclusters in which the nanoclusters comprise a plurality of nanoparticles having a core of nanoparticles arranged such that the surfaces of the nanoparticles contact adjacent nanoparticles, the nanoparticles comprise an active ingredient, and the nanocluster has a mass median aerodynamic diameter of from about 0.25 ?m to about 20 ?m.Type: GrantFiled: November 24, 2010Date of Patent: December 9, 2014Assignee: University of KansasInventors: Cory J. Berkland, Lianjun Shi, Nashwa El Gendy, Carl Plumley, Mark Bailey
-
Patent number: 8906419Abstract: The present invention is directed to a process of preparing beads coated with a water soluble drug for incorporation into a pharmaceutical composition comprising: (a) preparing a supersaturated drug solution containing a desired amount of drug, which is completely saturated at a first temperature but which is supersaturated at a second temperature which is below the first temperature; and (b) coating inert beads with the drug solution, said drug solution being maintained at or below the first temperature but above the second temperature, and said beads maintained at a second temperature, wherein the second temperature is less than the first temperature and wherein the solution containing the drug is supersaturated at the second temperature, as well as to the pharmaceutical compositions containing same.Type: GrantFiled: January 24, 2011Date of Patent: December 9, 2014Assignee: Nostrum Pharmaceuticals, Inc.Inventor: Nirmal Mulye
-
Patent number: 8901113Abstract: Effective methods and compositions to deter abuse of pharmaceutical products (e.g., orally administered pharmaceutical products) including but not limited to immediate release, sustained or extended release and delayed release formulations for drugs subject to abuse comprising at least 10% by weight hydroxypropylcellulose; polyethylene oxide; and a disintegrant selected from the group consisting of crospovidone, sodium starch glycolate and croscarmellose sodium; wherein the ratio of hydroxypropylcellulose to polyethylene oxide on a weight basis is between about 10:1 and 1:10.Type: GrantFiled: September 29, 2010Date of Patent: December 2, 2014Assignee: Acura Pharmaceuticals, Inc.Inventors: Ronald L. Leech, Rachelle L. Hall Yung, Albert W. Brzeczko
-
Intrathecal or epidural administration of 3-[(1S,25)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol
Patent number: 8895623Abstract: The present invention relates to a method of providing pain management in a subject wherein the administration of the composition does not result in any non-central nervous system mediated systemic effect in the subject. In particular, the present invention relates to a method of administering 3-[(1S,2S)-3-(dimethylamino)-1-ethyl-2-methyl-propyl]-phenol in a space that is void of thrombocytes.Type: GrantFiled: July 27, 2012Date of Patent: November 25, 2014Assignee: Gruenenthal GmbHInventors: Petra Bloms-Funke, Derek John Saunders, Eric Lang -
Publication number: 20140341988Abstract: Pharmaceutical dosage forms, particularly dosage forms in granular form having good palatability and capable of rapidly and completely dispersed in the mouth when orally administered.Type: ApplicationFiled: May 15, 2014Publication date: November 20, 2014Applicant: APR APPLIED PHARMA RESEARCH SAInventors: Alberto REINER, Giorgio REINER
-
Publication number: 20140343067Abstract: The present invention relates to a method of reducing cutaneous facial flushing caused by systemic use of phosphodiesterase type 5 (PDE5) inhibitors by topical facial dermatological application of an effective dose of a composition comprising at least one alpha adrenergic receptor agonist.Type: ApplicationFiled: October 12, 2012Publication date: November 20, 2014Inventors: Warren J. Scherer, Arthur Clapp, Philippe Andres
-
Publication number: 20140343159Abstract: Aspects of the present disclosure are directed to formulations that permit the solubilization and long term, stable storage of adrenergic agonist vasoconstrictors in organic solvents. Provided herein are formulations comprising about 250 mM to about 3000 mM of an acid salt of an adrenergic agonist vasoconstrictor dissolved in a pharmaceutically acceptable topical delivery vehicle comprising a water miscible, organic solvent having a water content of less than 40% by weight. Also provide are methods for using and kits containing such formulations.Type: ApplicationFiled: March 9, 2012Publication date: November 20, 2014Applicant: ProCertus Biopharm, Inc.Inventor: William E. Fahl
-
Patent number: 8889627Abstract: This invention provides a method of treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the subject laquinimod as an add-on therapy to or in combination with fingolimod. This invention also provides a package and a pharmaceutical composition comprising laquinimod and fingolimod for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides laquinimod for use as an add-on therapy or in combination with fingolimod in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and fingolimod in the preparation of a combination for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome.Type: GrantFiled: October 11, 2012Date of Patent: November 18, 2014Assignee: Teva Pharmaceutical Industries, Ltd.Inventors: Hussein Hallak, Nora Tarcic, Joel Flaxman Kaye
-
Publication number: 20140335206Abstract: This invention concerns a synergistic combination of a topical anesthetic and wound barrier forming agent capable of providing extended analgesia of ‘significant open wounds’ (that being, for example, a laceration, surgical incision, abrasion, ulcer or burn, but not being a minor cut, scratch, sting, burn or abrasion) in which conventional management alternatives (such as suturing and/or administration of injected or systemic analgesia) are impractical, unaffordable or otherwise unavailable.Type: ApplicationFiled: July 25, 2014Publication date: November 13, 2014Inventors: Meridith Sheil, Allan Giffard, Charles R. Olsson
-
Patent number: 8877793Abstract: The present invention is directed to the treatment of skin erythema as exhibited in rosacea and other conditions characterized by increased erythema (redness) of the skin. These conditions exhibit dilation of blood vessels due to a cutaneous vascular hyper-reactivity. In particular, the present invention is directed to a novel composition and method for the treatment of skin erythema using ?1-adrenergic receptor (?1-adrenoceptor) agonists incorporated into cosmetic, pharmacological or dermatological compositions for topical application to the skin.Type: GrantFiled: October 11, 2010Date of Patent: November 4, 2014Assignee: Allergan, Inc.Inventors: Stuart D. Shanler, Andrew Ondo
-
Publication number: 20140323423Abstract: Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, Alzheimer's disease, sleep disorders, Parkinson's disease, Attention Deficit Disorder and nicotine addiction involve synchronizing and tailoring the administration of nutraceuticals, medications and other substances (for example, stimulants) in accordance with the body's natural circadian rhythms, meal times and other factors. Improved control of blood glucose levels, extended alertness, and weight control, and counteracting of disease symptoms when they are at their worst are possible.Type: ApplicationFiled: May 2, 2014Publication date: October 30, 2014Applicant: Chrono Therapeutics, Inc.Inventors: Guy DiPierro, Steven A. Giannos
-
Publication number: 20140322341Abstract: Disclosed herein is a novel hemostatic patch that may be used to control and/or arrest bleeding in patients. The patch offers an effective but also minimally invasive way to control and/or arrest bleeding in a patient. The patch comprises a mucoadhesive and a compound that causes vasoconstriction. In a preferred aspect, the patch comprises chitosan and Neuropeptide Y. Also disclosed are methods of using the novel hemostatic patch.Type: ApplicationFiled: August 3, 2012Publication date: October 30, 2014Inventor: Diane RUBIN
-
Publication number: 20140323501Abstract: Immune-modulators of formula (I) below are prepared: A pharmaceutical composition contains the immune-modulators. The pharmaceutical composition is used as a drug, especially as an immune-modulating drug. The compound can be used in treatment of immune disorders and for immune suppression. Thus, for example, the compound can be used in treating hypo-immunity, rejection after organ transplantation and auto-immune disease.Type: ApplicationFiled: July 5, 2012Publication date: October 30, 2014Applicant: INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCESInventors: Weijuan Han, Haijing Zhang, Xiaojian Wang, Jing Jin, Gang Li, Yi Zhang, Qiong Xiao, Wanqi Zhou, Xiaoguang Chen, Dali Yin
-
Publication number: 20140316333Abstract: A dissolving solid solution perforator (SSP) patch for oral cavity administration may include at least one perforator. The at least one perforator may contain a first drug and be configured to pierce an outside layer of an oral cavity for promptly delivering the first drug. The at least one perforator may penetrate an epithelium layer of the oral cavity and to deliver the antimigraine drug into blood vessels in a submucosa layer.Type: ApplicationFiled: October 29, 2012Publication date: October 23, 2014Inventor: Sung-Yun KWON
-
Publication number: 20140309291Abstract: Compositions and methods for increasing resilience to the effects of stress are provided.Type: ApplicationFiled: November 9, 2012Publication date: October 16, 2014Inventors: Seema Bhatnagar, Willem Heydendael, Abhishek Sengupta
-
Patent number: 8859623Abstract: The invention is directed to methods and compositions of stabilizing phenylephrine formations. The composition has good time-dependent stability at low temperature and has no change in its outward appearance even after having been stored at least 6 months.Type: GrantFiled: November 14, 2013Date of Patent: October 14, 2014Assignee: Paragon Bioteck, Inc.Inventors: Patrick H. Witham, Sailaja Machiraju, Lauren Mackensie-Clark Bluett
-
Patent number: 8859622Abstract: Drug substances comprising a pharmaceutically acceptable organic acid addition salt of amine containing pharmaceutically active compounds useful for the treatment of a therapeutic ailment administration and exhibiting prophylactic properties when employed in non-therapeutic administration.Type: GrantFiled: April 3, 2008Date of Patent: October 14, 2014Assignee: Pisgah Laboratories, Inc.Inventors: David William Bristol, Clifford Riley King, Joseph Pike Mitchener, Jr., Vicki Haynes Audia
-
Publication number: 20140296183Abstract: A novel amine compound represented by the following formula (I), which is superior in immunosuppressive action, rejection suppressive action and the like, and shows reduced side effects such as bradycardia and the like, or a pharmaceutically acceptable acid addition salt thereof, or hydrates thereof, or solvate, as well as a pharmaceutical composition containing this compound and a pharmaceutically acceptable carrier. wherein R is a hydrogen atom or P(?O)(OH)2, X is an oxygen atom or a sulfur atom, Y is CH2CH2 or CH?CH, R1 is cyano or alkyl having a carbon number of 1 to 4 and substituted by a halogen atom(s), R2 is alkyl having a carbon number of 1 to 4 and optionally substituted by a hydroxyl group(s) or a halogen atom(s), R3 and R4 may be the same or different and each is a hydrogen atom or alkyl having a carbon number of 1 to 4, and n is 5-8.Type: ApplicationFiled: June 17, 2014Publication date: October 2, 2014Inventors: Masatoshi KIUCHI, Kaoru MARUKAWA, Nobutaka KOBAYASHI
-
Publication number: 20140294804Abstract: The invention relates to methods for treating pain disorders including neuropathic and inflammatory pain and to methods to reduce or eliminate nociceptive tolerance induced by opiate analgesic use by administering an agent that suppresses or blocks S1P biological activity.Type: ApplicationFiled: April 7, 2014Publication date: October 2, 2014Applicant: SAINT LOUIS UNIVERSITYInventor: Daniela SALVEMINI
-
Patent number: 8840923Abstract: Slow-release excipients which comprise an association of at least one glycogen and at least one alginate with an alkaline-earth metal salt are useful for the preparation of slow-release pharmaceutical formulations.Type: GrantFiled: December 23, 2008Date of Patent: September 23, 2014Assignee: Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.Inventors: Vincenzo Russo, Elisa Liberati, Nicola Cazzolla, Leonardo Marchitto, Lorella Ragni
-
Publication number: 20140271893Abstract: Phenylephrine particles suitable for solid, semi solid or liquid dosage forms are disclosed.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Applicant: McNeil-PPC, Inc.Inventors: Der-Yang Lee, Vincent Chen, Robert Shen
-
Publication number: 20140271541Abstract: Disclosed are pharmaceutical combinations comprising at least one S1P receptor agonist, as well as a method for treating demyelinating diseases, e.g. multiple sclerosis or disorders associated therewith or Guillain-Barré syndrome, comprising co-administration, e.g. concomitantly or in sequence, of a therapeutically effective amount of a) an S1P receptor agonist, and b) at least one co-agent shown to have clinical activity against at least one symptom of a demyelinating disease.Type: ApplicationFiled: March 18, 2014Publication date: September 18, 2014Applicant: NOVARTIS AGInventors: Carolyn Ann Foster, Peter C. Hiestand, Paul William Glue
-
Publication number: 20140271835Abstract: The present invention is directed to an immediate release and extended release capsule or capsule fill which mitigates the abuse of abuse-susceptible active pharmaceutical ingredients by direct intravenous injection. The fill comprises a parenteral abuse resistant liquid formulation which when mixed with water and heated, results in a turbid, viscous or bubbling mixture that is not injectable with a standard insulin syringe. The abuse-susceptible active pharmaceutical ingredient is selected from the group consisting of opiates, opioids, tranquillizers, stimulants and narcotics.Type: ApplicationFiled: March 11, 2014Publication date: September 18, 2014Inventor: Simone Wengner
-
Publication number: 20140275151Abstract: A liquid composition is provided. The composition includes at least one active pharmaceutical ingredient dissolved in a liquid carrier system. The liquid carrier includes polyethylene glycol and a co-solvent selected from the group consisting of: propylene glycol, glycerin, and a sugar alcohol. The composition is essentially dye tree, present as a single-phase at room temperature, and optionally contains water.Type: ApplicationFiled: March 7, 2014Publication date: September 18, 2014Inventors: Mahesh Sudhakar BHARATI, Houphouet Hyacinthe YARABE
-
Publication number: 20140271892Abstract: Phenylephrine particles suitable for solid, semi solid or liquid dosage forms are disclosed.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Applicant: McNeil-PPC, Inc.Inventor: McNeil-PPC, Inc.
-
Publication number: 20140256822Abstract: Disclosed are preparations and formulations of high thermodynamic activity lipophilic associations (LA), in which there is pairing between an ionizable pharmaceutical agent and a lipophilic species having ionic characteristics opposite to that of the pharmaceutical agent. Such lipophilic associations manifest high thermodynamic activity, as evidenced by their being predominantly in a liquid phase at room temperature or solvated in a lower-than-water dielectric solvent. Further the pharmaceutical agent being solubilized means that dissolution is not rate limiting to transmucosal absorption. This LA or LA-solvate is formulated into a low dielectric dosage form, from whence, upon the dosage form's hydration, the pharmaceutical agent is driven through the mucosal tissue and into systemic circulation. The invention therefore provides an enhanced transmucosal drug delivery system for ionizable pharmaceutical agents at or near physiological pH.Type: ApplicationFiled: March 10, 2014Publication date: September 11, 2014Inventor: John McCarty
-
Publication number: 20140255346Abstract: Embodiments of this invention include methods for detecting in vitro the presence in peripheral blood mononuclear cells (PBMCs), and in serum or plasma, of antibodies reactive to and of lymphocytes that are responsive to CNS antigens associated with Multiple Sclerosis (MS). These CNS antigens include, but are not limited to whole brain lysate and the myelin antigens myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG), MOG peptides (MOGps), proteolipid protein (PLP), and PLP peptides (PLPps). Stimulating PBMCs from patients with MS by CNS antigens cause B-lymphocytes to produce antibodies specific for CNS antigen, and causes T-lymphocytes to produce T-lymphocyte-specific cytokines, including interferon gamma (IFN-y), interleukin-2 (IL-2), or interleukin-17 (IL-17). In contrast, stimulating PBMCs from subjects without MS do not produce such responses.Type: ApplicationFiled: May 3, 2012Publication date: September 11, 2014Applicant: Cellular Technology, Ltd.Inventors: Stefanie Kuerten, Paul Lehmann
-
Publication number: 20140256688Abstract: A topical anorectal composition includes trimethylsiloxysilicate; at least one surfactant selected from the group consisting of sodium lauryl sulfate, alkyl- and alkoxy-dimethicone copolyol, polysorbate and a combination thereof; a non-polar volatile siloxane solvent; at least 15% (w/w) water; and a pharmaceutical agent selected from the group consisting of pramoxine, phenylephrine, hydrocortisone, salicylic acid, nitroglycerine, sildenafil, or their salts and combinations thereof, wherein the composition is sufficiently designed to dry within 60 seconds after application to the anorectal mucosa to form a dried composition, and wherein the dried composition forms: a flexible film, wherein the flexible film closely follows irregularities of the body surface as well as movement of the body surface, and (ii) a durable film, wherein the durable film does not crack or flake off and remains intact for more than 12 hours giving release of the pharmaceutical agent for an extended period of time.Type: ApplicationFiled: March 10, 2014Publication date: September 11, 2014Inventors: Evgenia Lozinsky, Eran Eilat
-
Publication number: 20140249180Abstract: A tau aggregation inhibitor reduces tau aggregation in cells. The tau aggregation inhibitor can include a catechol structure-containing compound or a salt thereof, and the catechol structure-containing compound can be one of isoprenaline, dopamine, dobutamine, levodopa, levodopa/carbidopa, trimetoquinol, hexoprenaline, methyldopa, and droxidopa. One example of the catechol structure-containing compound is isoprenaline, which can be d-enantiomer of isoprenaline or d/l-racemic mixture of isoprenaline. Tauopathies to be prevented or treated by the inhibitor include AD, Down's syndrome, Pick's disease, corticobasal degeneration, and progressive supranuclear palsy.Type: ApplicationFiled: October 3, 2012Publication date: September 4, 2014Applicants: National Center for Geriatrics and Gerontology, THE DOSHISHAInventors: Akihiko Takashima, Yoshiyuki Soeda, Hiroyuki Nagata, Yasuo Ihara, Tomohiro Miyasaka, Hachiro Sugimoto
-
Publication number: 20140248209Abstract: An anti-tumoral compound for the localized treatment of neoplastic pathologies of malignant kind that cannot be surgically removed or with a high risk of local recurrence, includes: a bicomponent injectable biologic glue; an antineoplastic substance; and an epinephrine-based solution. The compound may be used as an independent therapeutic treatment, as it allows to treat tumoral masses that are not surgically removable, or as a therapeutic treatment complementary to surgical removal or to known ablative techniques (laser, radiofrequency, microwaves, etc.) for a maximization of the efficiency of therapies reducing the risk of neoplastic relapses in the original surgical site. A process for the production of the antitumor compound is also described.Type: ApplicationFiled: October 21, 2011Publication date: September 4, 2014Applicant: Seventeen SRLInventor: Giulia Di Capua
-
Publication number: 20140248236Abstract: The disclosure provides methods of use of certain compounds that are useful for treating certain symptoms of endocrine disturbances, and in particular those associated with hot flashes.Type: ApplicationFiled: November 7, 2012Publication date: September 4, 2014Inventors: Michael G. Natchus, Richard Arrendale